Literature DB >> 24002912

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.

Véronique Loustaud-Ratti1, Paul Carrier, Chanlina Vong, Marie Essig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24002912     DOI： 10.1002/hep.26730

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.

Authors:  Alicia Gutierrez-Valencia; Rosa Ruiz-Valderas; Omar J Ben-Marzouk-Hidalgo; Almudena Torres-Cornejo; Nuria Espinosa; Juan R Castillo-Ferrando; Pompeyo Viciana; Luis F Lopez-Cortes
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

2.  Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

Authors:  Alessio Strazzulla; Giuseppe Coppolino; Concetta Di Fatta; Francesca Giancotti; Giuseppina D'Onofrio; Maria Concetta Postorino; Maria Mazzitelli; Selma Valerie Mammone; Innocenza Gentile; Laura Rivoli; Eleonora Palella; Tiziana Gravina; Chiara Costa; Vincenzo Pisani; Vincenzo De Maria; Giorgio Settimo Barreca; Nadia Marascio; Alfredo Focà; Giorgio Fuiano; Elio Gulletta; Carlo Torti
Journal:  World J Hepatol       Date:  2016-07-08

Review 3.  New therapies for hepatitis C: considerations in patients with renal impairment.

Authors:  Sarah Zimner-Rapuch; Nicolas Janus; Gilbert Deray; Vincent Launay-Vacher
Journal:  Drugs       Date:  2014-08       Impact factor: 11.431
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.